Laddar...
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
BACKGROUND: The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alon...
Sparad:
| I publikationen: | J Hematol Oncol |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7362563/ https://ncbi.nlm.nih.gov/pubmed/32664995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00929-8 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|